Virax Biolabs Group Limited (NASDAQ: VRAX)
$2.1600
+0.1500 ( +5.37% ) 74.9K
Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes and Human Papillomavirus.
Market Data
Open
$2.1600
Previous close
$2.0100
Volume
74.9K
Market cap
$8.73M
Day range
$2.0100 - $2.1500
52 week range
$0.6000 - $8.9999
SEC Filings
Form Type | Description | Pages | Date |
---|---|---|---|
6-k | Form 6-K | 3 | Nov 20, 2024 |
6-k | Form 6-K | 8 | Oct 31, 2024 |
6-k | Form 6-K | 2 | Oct 23, 2024 |
6-k | Form 6-K | 2 | Sep 30, 2024 |
6-k | Form 6-K | 6 | Aug 23, 2024 |
20-f | Annual reports | 106 | Aug 20, 2024 |
nt | Quarterly Reports | 1 | Aug 01, 2024 |
6-k | Form 6-K | 1 | Jun 11, 2024 |
6-k | Form 6-K | 2 | Apr 25, 2024 |
6-k | Form 6-K | 2 | Apr 16, 2024 |